CXCR2 and neoplasm: SB265610, a CXCR2 antagonist, may reverse immunosuppression by inhibiting the chemotaxis of MDSC to the tumor, thereby promoting the anti-tumor immunity of CD8+ T cells and inhibiting tumor immune escape (84).